Mauna Kea Technologies (Euronext: MKEA, FR0010609263), leader in the
Optical Biopsy market, announced today that its flagship Cellvizio
system is or will soon be available at three leading hospitals in
Brazil: ICESP (Cancer Institute of the São Paulo University), INCA
(National Cancer Institute in Rio de Janeiro), and FUGAST
(Gastroenterology Institute of Rio Grande do Sul). In addition, ANVISA,
the National Health Surveillance Agency in Brazil, has cleared the
company to sell its flagship miniprobe for direct pancreatic cyst
imaging, the AQ-Flex 19, as well as its first miniprobe for urology, the
UroFlex and its latest Optical Biopsy software platform, EVA, the
Endomicroscopy Virtual Assistant.
"Cellvizio is a critical addition to our endoscopy unit", said Dr Fauze
Maluf-Filho, Chief of Endoscopy at the Cancer Institute of the São Paulo
University, "We are very pleased to be one of the first hospitals in
Brazil to offer Optical Biopsy procedures to our patients who suffer
from a range of digestive diseases, including very hard to diagnose
Brazil is a fast-growing market for medical devices, and there is a
significant need for advanced technologies improving patient care. The
Cellvizio technology platform supports the efforts of state-of-the-art
hospitals across Brazil to offer best practice solutions in the
treatment of a wide range of pathologies and associated procedures.
"We were the first t demonstrate Cellvizio in Brazil at our 2012
ENEO/ENDOINCA international training course", commented Dr Simone
Guaraldi from the National Cancer Institute in Rio de Janeiro, "and we
are very excited to continue to be at the forefront of patient care with
the addition of Cellvizio to our state-of-the-art endoscopy unit".
"I am convinced that Cellvizio will bring a major value to our
Gastroenterology Center - and I am particularly pleased to offer Optical
Biopsy to our patients in Rio Grande do Sul in the same timing as Rio de
Janeiro and Sao Paulo" said Dr Claudio Rolim Teixeira, from the
Gastroenterology Institute of Rio Grande do Sul - FUGAST.
Sacha Loiseau, CEO and founder of Mauna Kea Technologies, added: "With
three centers of excellence providing care with Cellvizio and our full
range of products now cleared, we are continuing to make significant
progress in bringing the advantages of our technology to patients in the
fast-growing Brazil and in other markets throughout Latin America."
Mauna Kea Technologies confirms that it is eligible for the new
PEA-PME SME equity savings plan setup whose implementing decree was
published in the Journal Officiel (official journal) on 4 March 2014
(decree n°2014-283). This new savings device, which benefits from the
same fiscal advantages as the PEA equity savings plan, must consist of
at least 75% of SME and VSE securities, including 50% in shares, and has
a ceiling of €75,000.
About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company dedicated to
the advent of optical biopsy. The company researches, develops and
markets innovative tools to visualize and detect cellular abnormalities
during endoscopic procedures. Its flagship product, Cellvizio®, a
probe-based Confocal Laser Endomicroscopy (pCLE) system, provides
physicians and researchers high-resolution cellular views of tissue
inside the body. Large, international, multicenter clinical trials have
demonstrated Cellvizio's ability to help physicians more accurately
detect early forms of disease and make treatment decisions immediately.
Designed to improve patient outcomes and reduce costs within a hospital,
Cellvizio can be used with almost any endoscope. Cellvizio has 510(k)
clearance from the U.S. Food and Drug Administration and the European
CE-Mark for use during digestive, pulmonary and urologic endoscopy
procedures, including pancreatic and biliary endoscopic explorations as
well as fine needle aspiration procedures.
For more information on Mauna Kea Technologies, visit www.maunakeatech.com
[ Back To NFVZone's Homepage ]